Advertisement
Canada markets open in 4 hours 36 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7316
    +0.0018 (+0.25%)
     

  • CRUDE OIL

    83.02
    +0.21 (+0.25%)
     

  • Bitcoin CAD

    87,229.46
    -3,735.72 (-4.11%)
     

  • CMC Crypto 200

    1,358.44
    -24.13 (-1.74%)
     

  • GOLD FUTURES

    2,340.40
    +2.00 (+0.09%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,500.75
    -163.75 (-0.93%)
     

  • VOLATILITY

    16.13
    +0.16 (+1.00%)
     

  • FTSE

    8,096.73
    +56.35 (+0.70%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today

Eric Volkman, The Motley Fool
·2 min read
Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today

Infinity Pharmaceuticals (NASDAQ: INFI) got off to a market-beating start this week as its shares zoomed 3.8% higher Monday, on the back of new analyst coverage that made an extremely bullish case for investing in the biotech. H.C. Wainwright's Michael King Jr. is the prominent new Infinity bull. King points out that the company's lead pipeline candidate, the cancer treatment eganelisib, "has shown compelling activity both as a single agent as well as in combination with commonly used immune checkpoint inhibitors."

Continue reading